GlassScriptPhysician profile
Susan Lynn Vild
NPI 1801899083
$4,002.54
in general payments reported to CMS, 2019-2025
38 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $872 · 2022: $1,095 · 2023: $1,012 · 2024: $684 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.95 | 2021-2024 | |
| Novo Nordisk INC | $465.13 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Inspire Medical Systems, INC. | $265.91 | 2023-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $252.72 | 2022-2025 | |
| Glaxosmithkline, LLC. | $181.38 | 2022-2023 | Trelegy Ellipta, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $160.56 | 2021-2023 | Eliquis |
| Idorsia Pharmaceuticals US INC | $124.99 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $123.54 | 2023-2024 | Xarelto |
| Avadel Cns Pharmaceuticals, LLC | $119.70 | 2025 | Lumryz |
| Alkermes, INC. | $119.39 | 2024 | Vivitrol |
| Novartis Pharmaceuticals Corporation | $118.22 | 2021-2023 | |
| Pfizer INC. | $108.07 | 2021-2023 | |
| Exact Sciences Corporation | $105.24 | 2023-2024 | Cologuard Collection Kit |
| Sk Life Science, INC. | $95.21 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $90.95 | 2025 | Iqirvo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Vild listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.